BUD - Anheuser-Busch InBev SA/NV

NYSE - NYSE Delayed Price. Currency in USD
72.52
-0.01 (-0.01%)
At close: 4:02PM EST

72.52 0.00 (0.00%)
After hours: 4:49PM EST

Stock chart is not supported by your current browser
Previous Close72.53
Open72.17
Bid72.01 x 1200
Ask73.49 x 800
Day's Range71.98 - 72.85
52 Week Range64.55 - 117.06
Volume1,215,583
Avg. Volume2,134,553
Market Cap139.803B
Beta (3Y Monthly)1.08
PE Ratio (TTM)21.06
EPS (TTM)3.44
Earnings DateN/A
Forward Dividend & Yield3.30 (4.55%)
Ex-Dividend Date2018-11-27
1y Target Est88.66
Trade prices are not sourced from all markets
  • Barrons.com13 hours ago

    The Maker of Budweiser Is Going an a ‘Debt Diet’

    The latest bond sale by Anheuser-Busch InBev, the Budweiser maker and world’s biggest brewer, should help relieve some of its debt pressures.

  • Tilray Shares Rally as Investor Plans Not to Sell Shares
    Zacksyesterday

    Tilray Shares Rally as Investor Plans Not to Sell Shares

    Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.

  • CNBC2 days ago

    Stocks making the biggest moves premarket: GG, LULU, AAPL, PCG & more

    These are the stocks posting the largest moves before the bell.

  • Where Constellation Brands’ Valuation Stands after Its Q3 Results
    Market Realist2 days ago

    Where Constellation Brands’ Valuation Stands after Its Q3 Results

    Constellation Brands' Guidance Cut Overshadowed Its Q3 Results (Continued from Prior Part) ## STZ’s valuation Constellation Brands (STZ) was trading at 12-month forward PE multiple of 15.4x as of the end of the day on January 9. Constellation Brands’ forward valuation multiple fell 13.1% on January 9 as the company lowered its guidance for fiscal 2019, which ends on February 28, 2019. Higher interest expenses associated with the company’s financing of its stake in Canopy Growth (CGC) and weakness in the performance of its wine and spirits business are expected to adversely affect its fiscal 2019 earnings. As of January 9, Anheuser-Busch InBev (BUD), Molson Coors Brewing (TAP), and Brown-Forman (BF.B) are trading at 12-month forward PE multiples of 17.3x, 12.4x, and 27.1x, respectively. Constellation Brands is trying to boost its performance by focusing on premium brands in the beer and wine and spirits businesses. The company is exploring strategic alternatives to address the weakness in the $11 and below price point in the wine and spirits business. Constellation Brands is also focusing on innovation to drive its top line growth. Its Corona Premier, a low-calorie beer, has achieved tremendous success since its introduction. In the wine and spirits business, the company’s latest product introductions include Meiomi Rosé and SVEDKA Blue Raspberry. Constellation Brands has over a 36% stake in leading cannabis company Canopy Growth and has the option of increasing its stake to over 50%. Constellation’s significant investment in Canopy Growth gives it the opportunity to capitalize on the growth prospects in the global medicinal and recreational cannabis market. ## Analysts’ expectations Analysts expect Constellation Brands’ sales to rise 6.7% to $8.1 billion and its adjusted EPS to rise 6.8% to $9.31 in fiscal 2019. In fiscal 2020, the company’s sales growth and adjusted EPS growth are expected to be 6.5% and 5.9%, respectively. Its premium Mexican beer brands are likely to be the key drivers of its future growth. Browse this series on Market Realist: * Part 1 - Constellation Brands’ Guidance Cut Overshadowed Its Q3 Results * Part 2 - How Constellation Brands’ Q3 Earnings Shook Out * Part 3 - Assessing Constellation Brands’ Q3 Sales Growth

  • Anheuser-Busch InBev SA/NV (EBR:ABI): What Are The Future Prospects?
    Simply Wall St.2 days ago

    Anheuser-Busch InBev SA/NV (EBR:ABI): What Are The Future Prospects?

    After Anheuser-Busch InBev SA/NV's (EBR:ABI) earnings announcement in September 2018, analyst consensus outlook appear cautiously optimistic, with earnings expected to grow by 24% in the upcoming year compared with the Read More...

  • TheStreet.com2 days ago

    Shares of Budweiser Brewer AB InBev Frothing Over Possible Asian IPO

    were hopping Friday amid talk of a potential IPO of its Asian operations by the global brewer. AB InBev's stock price rose 4.20% to close at $73.73 following a report by Bloomberg News the Belgium-based beer giant is discussing with advisers whether to turn its Asian operations into a publicly traded company. The deal could raise as much as $5 billion for the maker of Budweiser, which has been struggling under a high debt load since its $100 billion deal in 2016 for SABMiller Plc., the news service reports.

  • Reuters4 days ago

    AB InBev considers partial IPO of Asian business -bankers

    BRUSSELS/HONG KONG (Reuters) - Anheuser-Busch InBev (ABI.BR), the world's largest brewer, is considering raising billions of dollars in a partial flotation of its Asian operations, two Asian banking sources said, in a deal that would help to ease its debt burden. The Belgium-based maker of Budweiser, Corona and Stella Artois has been discussing a possible multibillion-dollar listing in Hong Kong, one banker said on Friday. AB InBev declined to comment on the matter.

  • Reuters4 days ago

    AB InBev considers partial IPO of Asian business -bankers

    BRUSSELS/HONG KONG, Jan 12 (Reuters) - Anheuser-Busch InBev , the world's largest brewer, is considering raising billions of dollars in a partial flotation of its Asian operations, two Asian banking sources said, in a deal that would help to ease its debt burden. The Belgium-based maker of Budweiser, Corona and Stella Artois has been discussing a possible multibillion-dollar listing in Hong Kong, one banker said on Friday. AB InBev declined to comment on the matter.

  • Is Craft Beer Still Worth Investing In?
    Motley Fool4 days ago

    Is Craft Beer Still Worth Investing In?

    It pays to be picky.

  • 3 Back-of-the-Shelf Consumer Stocks With Growth and Income
    InvestorPlace4 days ago

    3 Back-of-the-Shelf Consumer Stocks With Growth and Income

    Many tend to ignore consumer stocks not oriented toward the latest technology. Consumers and investors tend to focus on companies that produce new gadgets or bring the next wave of tech innovation. Many "boring" consumer stocks that have less of a tech focus, however, offer an impressive track record with dividends. This serves as an advantage over a tech industry, which tends to lag the S&P 500 when it comes to offering dividend stocks. Due in large part to dividends and a loyal customer base, consumer stocks tend to offer stability lacking in some of these more exciting stocks. Also, contrary to popular belief, many of these companies have become innovation leaders. Although the press may not always report it, these firms often pioneer new products that place them on the cutting edge in their industries. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 A-Rated Stocks to Buy That The Smart Money Is Piling Into The following three companies lead this innovation. They also offer growth rates, valuations and dividend yields that should draw the attention of stock buyers. Source: Shutterstock ### AbbVie (ABBV) Admittedly, AbbVie (NYSE:ABBV) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. However, when an equity offers an almost single-digit forward price-to-earnings (P/E) ratio, double-digit profit growth and the third-highest dividend yield among dividend aristocrats, I cannot leave it off in good conscience. ABBV stock trades a perfect storm for buyers. The patent on Humira faces patent expirations across the world. This has inspired a wave of selling in AbbVie. Despite this, analysts believe the company's drug pipeline will keep profits growing at double-digit rates. This has led to a forward PE ratio that stands at about 10.1. This perfect storm also applies to the firm's payouts. Due to its previous history as part of Abbott Laboratories (NYSE:ABT), ABBV holds dividend aristocrat status. When a stock hikes its payout for 46 years as AbbVie has, the stock price depends heavily on keeping this streak alive. Even better, ABBV has not made not offered a token hike in the payout merely to maintain the dividend aristocrat status. AbbVie went further, taking the payout from $2.56 per share in 2017 to $3.59 per share in 2018 to $4.28 per share this year. Approving such hikes when they face intense pressure to raise the payout every year shows a strong belief in its own future. Considering the low P/E ratio, the profit levels, and the dividend growth amounts, ABBV becomes one of the more obvious choices among consumer stocks. Source: Peyri Herrera via Flickr (Modified) ### Altria Group (MO) Few consumer stocks reflect resilience better than Altria (NYSE:MO). This year will mark 55 years since the U.S. Surgeon General released their report warning on the dangers of smoking. Amid anti-smoking campaigns, increasing tobacco taxes, and multi-billion dollar legal settlements, MO stock should have sunk into obscurity. Instead, Altria has become an unlikely success story. Despite the hostile environment for tobacco, the company continues to find opportunity. Currently, it invests in both smokeless tobacco and alcohol. It currently holds a 10.2% stake in Anheuser Busch-InBev (NYSE:BUD), for example. Also, despite legal barriers, it has also turned to the emerging marijuana sector. In late 2018, Altria purchased a 45% stake in Cronos (NASDAQ:CRON) for $1.8 billion. Even with the hostile business environment, MO stock manages to maintain a generous dividend. The current dividend of $3.20 per share yields almost 6.6%. Although MO does not hold dividend aristocrat status, the payout has increased in most years. As a result, MO stock has long remained a dividend powerhouse. Those who bought the equity in 2000 and reinvested the dividends receive their original investment back every year in dividends alone. The same holds true for those who bought in 1985 and spent or invested the payouts elsewhere. The company also looks attractive from a valuation and growth perspective. The forward P/E stands at 11.3. Moreover, analysts predict a 7.5% profit growth rate this year. Also, they expect those profit increases to remain in the high-single-digits for years to come. With its successes in related business, and its ability to maintain growth despite strong anti-tobacco sentiment, Altria should continue to stand out among consumer stocks. Source: Shutterstock ### General Mills (GIS) Despite producing recession-proof products, General Mills (NYSE:GIS) and its direct peers have endured years of struggle. An increasing interest in fresh and organic foods has diminished demand for the packaged foods General Mills has produced. As a result, it has seen both revenue and profits steadily fall over the last few years. This has taken GIS stock to levels first seen in 2012. However, a turnaround could occur soon. General Mills has begun to pivot to reflect consumer tastes. The company owns brands such as Cascadian Farm, Larabar, and Muir Glen that produce certified organic foods. Such products have helped revenues and profits turns around. After years of falling numbers, analysts predict a 5.5% increase in profits next year. Revenues have already begun to improve as Wall Street expects a 7.7% increase in sales growth for this year. Also, due to the years of decline, GIS stock trades at 12.7 forward earnings. Although this would not impress investors in a shrinking business, it begins to appear reasonable with growth returning. Also, with a five-year average P/E of 20.6, investors will likely enjoy a nice gain by waiting for the multiple to return to its long-term average. Even better for income-oriented investors, the $1.96 per share dividend yields around 4.75%. Since they have achieved a 15-year streak of dividend increases, another payout hike will likely come this year. Both consumers and investors have waited a long time for packaged food companies to embrace more natural foods. General Mills has finally made that move. With its attractive valuations and dividend yields, GIS stock should find a place among the more attractive high-dividend consumer stocks. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 3 Back-of-the-Shelf Consumer Stocks With Growth and Income appeared first on InvestorPlace.

  • ‘It's Definitely Risk On’: Rush to Bond Market Begins in U.S.
    Bloomberg4 days ago

    ‘It's Definitely Risk On’: Rush to Bond Market Begins in U.S.

    “There’s definitely been a change in tone, and it’s definitely risk on,” said Matt Kennedy, a high-yield portfolio manager at Angel Oak Capital Advisors. While investors still maintain longer-term fears about economic growth and trade tensions, the near-term weakness warrants taking exposure at the margins, several Wall Street strategists said this week.

  • InvestorPlace4 days ago

    Will Tilray’s Dealmaking Lift Tilray Stock in 2019?

    Tilray (NASDAQ:TLRY) announced on Dec. 18 that it was expanding its partnership with Sandoz, part of drug giant Novartis (NYSE:NVS). Under the deal, which caused Tilray stock to rally, Sandoz's global-sales team will market Tilray's medical-cannabis products. Four days later, Tilray announced that it was partnering with Anheuser-Busch (NYSE:BUD) to research cannabis-infused drinks. That news also created a buzz around Tilray stock. Inevitably, as cannabis companies in Canada and elsewhere stake their claims to different parts of the cannabis industry, comparisons will be made to the Gold Rush of the 1800s. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks at Risk of the Global Smartphone Slowdown And as in the days of the Gold Rush, there will be winners, losers, and posers. ### Is Tilray Stock a Winner, a Loser or a Poser? Unlike Cronos Group (NASDAQ:CRON) and Canopy Growth (NYSE:CGC), Tilray isn't interested in getting investments from large companies, as TLRY prefers to remain completely independent. "We obviously want to partner with other global pioneers and other leaders in their respective sectors," Tilray CEO Brendan Kennedy said about the partnerships. "We think it's too early to give up control of our own destiny." Those appear to be the words of someone who's going to remain CEO of an independent TLRY for a long time. Of course, it could also be PR speak for "We haven't gotten the right offer just yet." Whatever the true motivations of Tilray's CEO and board, its partnerships could prove to be very beneficial for Tilray stock over the long-term. However, it's not uncommon for big, multinational companies to blow hot and cold. Either of Tilray's partners could lose interest, pay a breakup fee, and end the partnership. Getting a big investment like the one that Canopy's gotten from Constellation Brands (NYSE:STZ) is far more permanent; it's also a sign that Canopy is serious about being a smaller piece of a much bigger pie. Tilray might believe that it's in control of its destiny at the moment, but it can lose that control very quickly. TLRY had operating losses of $34 million on $27.6 million in sales through the first nine months of its fiscal year. To win the cannabis wars, companies need deep pockets and experience. Canopy has both. Tilray doesn't. ### It's Not a Poser I don't think there's any way you can consider Tilray a poser. Anheuser-Busch and Sandoz wouldn't have signed on to these deals if they had a sniff of doubt about Tilray's bona fides. However, as InvestorPlace's Luke Lango pointed out in late December, the BUD partnership is not a huge catalyst that can move TLRY stock back into triple digits. "A $50 million commitment from AB InBev (a $130 billion company) is a drop in the ocean," Lango stated in an article published on Dec. 28. "The language in the press release also doesn't imply that AB InBev and Tilray will be 'lifetime partners,' and that stands in stark contrast to the bullish language in the Cronos and Canopy deal press releases." Tilray's CEO, Brendan Kennedy, believes that there will be three cannabis companies with $100 billion valuations, and he hopes that Tilray stock will be one of them. He also thinks that Tilray will be one of three companies in the sector with annual sales of $50 billion. That seems brash for a company that's projected to generate just $140 million of sales in 2019. Kennedy might want to tone down the rhetoric because it likely will come back to bite him in the rear end. ### The Bottom Line on Tilray Stock While Tilray has been in the news a lot in recent weeks, the company's dealmaking has done little to move TLRY stock. Tilray stock can only rise meaningfully if the company delivers better results in the fourth quarter or if it changes its philosophy and sells a chunk of its business to a company like Diageo (NYSE:DEO). Investors want results now. That's a terrible situation for companies like Tilray that have long-range plans. As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Will Tilraya€™s Dealmaking Lift Tilray Stock in 2019? appeared first on InvestorPlace.

  • Anheuser-Busch InBev Soars on Possible IPO of Asian Business
    Bloomberg4 days ago

    Anheuser-Busch InBev Soars on Possible IPO of Asian Business

    The Leuven, Belgium-based maker of Budweiser has been talking with potential advisers about the possibility of listing its Asian business, according to the people. AB InBev may seek to value its entire Asian business at around $70 billion through the share sale, though the eventual figure would depend on market demand and growth prospects for the business, the people said. Deliberations are at an early stage, and AB InBev could opt against pursuing a transaction, according to the people.

  • Bud Light debuts bigger nutrition labels
    Associated Press4 days ago

    Bud Light debuts bigger nutrition labels

    DETROIT (AP) — Beer drinkers can't claim blissful ignorance for much longer.

  • AB InBev Asia IPO Could Put It Back on M&A Wagon
    Bloomberg4 days ago

    AB InBev Asia IPO Could Put It Back on M&A Wagon

    AB InBev has struggled to grow out of the debt burden it took on with the $123 billion purchase of SABMiller in 2016. The weighted average maturity of AB InBev’s debt is 13 years. AB InBev’s colossal refinancing on Thursday, which raised more than originally planned, certainly helped.

  • What Drove Constellation Brands’ Impressive Beer Sales?
    Market Realist5 days ago

    What Drove Constellation Brands’ Impressive Beer Sales?

    Constellation Brands' Guidance Cut Overshadowed Its Q3 Results (Continued from Prior Part) ## Strong demand is driving growth Constellation Brands’ (STZ) top line growth in the third quarter of fiscal 2019, which ended on November 30, 2018, continued to be driven by demand for the company’s Mexican beer brands. Its beer business’s sales rose 16.0% to $1.2 billion in the quarter. Constellation Brands’ Modelo and Corona brands continued to deliver impressive results driven by strong distribution gains and innovations. Rival Molson Coors’ (TAP) sales rose 1.8% to $2.9 billion in the third quarter of 2018 driven by higher pricing, volume growth in Europe, the United States, and Canada, and the impact of a favorable product mix in Europe. Anheuser-Busch InBev’s (BUD) revenue fell ~10% to $13.3 billion in the third quarter of 2018, while its organic revenue rose 4.5%. Anheuser-Busch InBev attributed its organic revenue growth to the strong performance of its premium brands and its revenue-management initiatives. ## Beer business’s performance The double-digit growth in Constellation Brands’ beer sales was driven by higher volumes in its Mexican beer category, which contributed $143.8 million to its top line, and a $28.9 million contribution resulting from higher pricing in select markets. The 14.1% rise in the business’s shipment volumes in the quarter was driven by continued consumer demand, increased marketing efforts, product introductions, and the favorable timing of shipments. ## Capacity expansion To support the strong demand for its Mexican beer brands, Constellation Brands has been making significant investments in increasing its production capacity. The company expects to complete its Nava brewery capacity expansion by the end of fiscal 2019. It expects the 5-million-hectoliter capacity expansion at its Obregon facility to be completed ahead of schedule by the end of fiscal 2021. Despite a challenging political environment, the company is continuing the construction of its Mexicali facility. According to the company, this facility will represent only 10% of its overall beer capacity in Mexico. The company expects its Nava and Obregon facilities to produce 400 million cases of beer when they’re completed. Constellation Brands now expects its fiscal 2019 beer business sales to be at the high end of its guidance range of 9%–11% growth. Next, we’ll look at the factors that influenced Constellation Brands’ fiscal 2019 third-quarter margins. Continue to Next Part Browse this series on Market Realist: * Part 1 - Constellation Brands’ Guidance Cut Overshadowed Its Q3 Results * Part 2 - How Constellation Brands’ Q3 Earnings Shook Out * Part 3 - Assessing Constellation Brands’ Q3 Sales Growth

  • Financial Times5 days ago

    [$$] AB InBev: no mugs

    Beer drinkers are maligned as overweight guzzlers. A balance sheet has been bloated with successive acquisitions. AB InBev’s market value has waddled downhill ever since the October 2016 SABMiller deal.

  • Financial Times5 days ago

    [$$] Brewer AB InBev weighs public listing of Asia unit

    is considering listing a minority stake in its Asia operations, which would enable the world’s biggest brewer to more quickly pay down its $100bn debt load. The maker of Budweiser and Stella Artois beers has been in early-stage discussions with bankers in New York and Hong Kong, and could move ahead with a listing this year, according to a person involved in the talks. Bloomberg first reported the news on Friday that AB InBev could raise more than $5bn in proceeds from such an initial public offering, valuing the entire Asian business at about $70bn.

  • Moody's5 days ago

    Anheuser-Busch InBev Worldwide Inc -- Moody's rates Anheuser-Busch InBev Bonds at Baa1; outlook stable

    Moody's Investors Service ("Moody's") today assigned Baa1 ratings to Anheuser-Busch InBev Worldwide Inc., guaranteed by Anheuser-Busch InBev SA/NV ("ABI") and affiliates, for approximately $15.5 billion of notes to be issued in multiple tranches. The Baa1 rating reflects ABI's strong qualitative fundamentals offset by Moody's expectation that leverage will remain high for the next few years.

  • AB InBev Looks for a Long-Term Commitment
    Bloomberg5 days ago

    AB InBev Looks for a Long-Term Commitment

    This is a somewhat bold move for a company that’s just a month removed from a Moody’s Investors Service downgrade to the lowest investment-grade tier. After all, analysts pinned the rating cut squarely on the fact that AB InBev’s leverage is expected to remain elevated in the near future. Buoyed by a broad feeling of risk-taking across global markets, the Bloomberg Barclays U.S. Corporate High-Yield Bond Index is up 3 percent already this year, and investment-grade company debt is outperforming Treasuries.

  • AB InBev Looks for a Long-Term Commitment
    Bloomberg5 days ago

    AB InBev Looks for a Long-Term Commitment

    This is a somewhat bold move for a company that’s just a month removed from a Moody’s Investors Service downgrade to the lowest investment-grade tier. After all, analysts pinned the rating cut squarely on the fact that AB InBev’s leverage is expected to remain elevated in the near future. Buoyed by a broad feeling of risk-taking across global markets, the Bloomberg Barclays U.S. Corporate High-Yield Bond Index is up 3 percent already this year, and investment-grade company debt is outperforming Treasuries.

  • CNBC5 days ago

    Budweiser brewer spends more than ever on this year's Super Bowl, buys eight ad spots

    Brewer Anheuser-Busch InBev (A-B InBev) is spending top dollar at the Super Bowl 2019, buying five-and-a-half minutes of airtime, its biggest media spend for the event to date. It will promote its Budweiser, Bud Light, Stella Artois, Michelob Ultra and Bon & Viv Spiked Seltzer brands over eight commercials.

  • Financial Times6 days ago

    [$$] Brewer AB InBev returns to market with $15.5bn mega bond sale

    was finalising the pricing for a $15.5bn bond offering on Thursday, in what would be the largest corporate debt sale of the year. Proceeds from the debt sale will be used to refinance some of the debt taken on by the company after it acquired SABMiller in 2016. The bond sale tests AB InBev’s draw after the company was downgraded by Moody’s last month, with the rating agency citing the company’s $100bn debt load.

  • Softness in Beer Hurt Alcohol Stocks, Can Cannabis Change Fate?
    Zacks6 days ago

    Softness in Beer Hurt Alcohol Stocks, Can Cannabis Change Fate?

    Softness in Beer Hurt Alcohol Stocks, Can Cannabis Change Fate?

  • Why Constellation Brands Has Fallen More than 12% Today
    Market Realist6 days ago

    Why Constellation Brands Has Fallen More than 12% Today

    Why Constellation Brands Has Fallen More than 12% Today ## Constellation Brands On January 9, Constellation Brands (STZ) reported its third-quarter results before the market opened. The third quarter ended on November 30. The company’s adjusted EPS rose 18.5% to $2.37 in the third quarter of fiscal 2019 from $2.00 a year ago. The EPS was better than analysts’ consensus estimates of $2.06. However, the company’s stock fell more than 12% during the pre-market trading session on January 9. Let’s take a look at what could be driving the pessimism. ## Positive highlights In the last quarter ending on November 30, Constellation Brands’ beer shipments rose 14.1% YoY (year-over-year), while its wine shipments were stagnant. The company’s third-quarter adjusted revenues rose 9.6% YoY to ~$2.0 billion. Constellation Brands’ third-quarter adjusted net profit was $461.7 million—up 14.7% YoY with a net profit margin of 23.4% compared to 22.4% a year ago. ## What’s driving the pessimism? In Constellation Brands’ earnings report for the third quarter of fiscal 2019, the company lowered its fiscal 2019 earnings guidance to $9.20–and $9.30 from $9.60–$9.75 per share. In the report, the company said, “The wine and spirits business now expects net sales and operating income to decline low-single digits for fiscal 2019.” Despite stronger-than-estimated third-quarter results, Constellation Brands’ weaker fiscal 2019 guidance could be driving the stock lower in the pre-market session on January 9. In 2018, Constellation Brands lost 29.6%, while Molson Coors (TAP), Anheuser-Busch InBev (BUD), and Brown-Forman (BF.B) fell 31.6%, 41.0%, and 11.8%, respectively. Tilray (TLRY) settled with 15.8% gains on January 8. To learn more, read Why Tilray Surged Over 14% Today.